HomeCompareOCEL vs NOBL

OCEL vs NOBL: Dividend Comparison 2026

OCEL yields 72.93% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCEL wins by $1.18M in total portfolio value
10 years
OCEL
OCEL
● Live price
72.93%
Share price
$2.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.20M
Annual income
$325,655.22
Full OCEL calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — OCEL vs NOBL

📍 OCEL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCELNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCEL + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCEL pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCEL
Annual income on $10K today (after 15% tax)
$6,198.72/yr
After 10yr DRIP, annual income (after tax)
$276,806.94/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, OCEL beats the other by $276,594.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCEL + NOBL for your $10,000?

OCEL: 50%NOBL: 50%
100% NOBL50/50100% OCEL
Portfolio after 10yr
$613.5K
Annual income
$162,952.50/yr
Blended yield
26.56%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCEL buys
0
NOBL buys
0
No recent congressional trades found for OCEL or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCELNOBL
Forward yield72.93%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1.20M$22.9K
Annual income after 10y$325,655.22$249.78
Total dividends collected$1.03M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: OCEL vs NOBL ($10,000, DRIP)

YearOCEL PortfolioOCEL Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$17,993$7,292.62$10,917$217.08+$7.1KOCEL
2$31,515$12,262.92$11,903$221.48+$19.6KOCEL
3$53,795$20,073.98$12,962$225.68+$40.8KOCEL
4$89,585$32,023.91$14,099$229.68+$75.5KOCEL
5$145,696$49,840.41$15,319$233.49+$130.4KOCEL
6$231,650$75,755.11$16,628$237.10+$215.0KOCEL
7$360,433$112,567.38$18,033$240.53+$342.4KOCEL
8$549,352$163,689.57$19,539$243.78+$529.8KOCEL
9$820,973$233,165.47$21,154$246.86+$799.8KOCEL
10$1,204,096$325,655.22$22,884$249.78+$1.18MOCEL

OCEL vs NOBL: Complete Analysis 2026

OCELStock

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent, which is in Phase I/II clinical trial to treat COVID-19. The company also provides independent education, advertising, and marketing services to medical and other healthcare, anti-aging, and regenerative service providers. It has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was incorporated in 2011 and is headquartered in Miami, Florida.

Full OCEL Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this OCEL vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCEL vs SCHDOCEL vs JEPIOCEL vs OOCEL vs KOOCEL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.